| 9.415 0.225 (2.45%) | 09-14 13:36 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.46 | 1-year : | 11.98 |
| Resists | First : | 9.81 | Second : | 10.26 |
| Pivot price | 9.76  |
|||
| Supports | First : | 9.1 | Second : | 7.57 |
| MAs | MA(5) : | 9.25 |
MA(20) : | 9.77 |
| MA(100) : | 9.45 |
MA(250) : | 9.58 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.2 |
D(3) : | 9.6 |
| RSI | RSI(14): 38.6 |
|||
| 52-week | High : | 11.05 | Low : | 8.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HLN ] has closed above bottom band by 25.4%. Bollinger Bands are 107.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.28 - 9.37 | 9.37 - 9.42 |
| Low: | 8.91 - 9.03 | 9.03 - 9.1 |
| Close: | 9.05 - 9.25 | 9.25 - 9.36 |
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Fri, 11 Sep 2026
Avoiding Lag: Real-Time Signals in (HLN) Movement - Stock Traders Daily
Tue, 08 Sep 2026
Haleon slips Tuesday, underperforms market - MarketWatch
Mon, 07 Sep 2026
Haleon plc (HLN) Stock Analysis: Exploring a 24.94% Potential Upside in Healthcare Investment - DirectorsTalk Interviews
Tue, 01 Sep 2026
Haleon Plc (HLN): Investor Outlook On A 19.94% Potential Upside In Healthcare Stocks - DirectorsTalk Interviews
Tue, 01 Sep 2026
Haleon sets 8.80B voting shares for FCA thresholds | HLN SEC Filing - Form 6-K - Stock Titan
Mon, 31 Aug 2026
Haleon: Decent Growth Prospects, But Still Not A Bargain (NYSE:HLN) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 4,400 (M) |
| Shares Float | 4,430 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 13.5 (%) |
| Shares Short | 13,300 (K) |
| Shares Short P.Month | 12,630 (K) |
| EPS | 0.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.98 |
| Profit Margin | 14.5 % |
| Operating Margin | 23.9 % |
| Return on Assets (ttm) | 5 % |
| Return on Equity (ttm) | 10 % |
| Qtrly Rev. Growth | 2.2 % |
| Gross Profit (p.s.) | 1.66 |
| Sales Per Share | 2.53 |
| EBITDA (p.s.) | 0.64 |
| Qtrly Earnings Growth | -4.5 % |
| Operating Cash Flow | 2,650 (M) |
| Levered Free Cash Flow | 1,800 (M) |
| PE Ratio | 19.14 |
| PEG Ratio | 2.3 |
| Price to Book value | 1.88 |
| Price to Sales | 3.7 |
| Price to Cash Flow | 15.57 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|